SUMMARY In a prospective clinical and biochemical study of 16 patients treated with high doses of an immunoglobulin product that had been modified for intravenous use by mild pepsin treatment at pH 4 no evidence of hepatitis could be found. This contrasts with recent reports that intravenous immunoglobulin products can apparently transmit non-A, non-B hepatitis.
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Intravenous immunoglobulin is increasingly being used as a substitution treatment for hypogammaglobulinaemia' and as an empirical treatment for several autoimmune disorders such as idiopathic thrombocytopenic purpura.2 We report prospective biochemical and virological studies carried out as part of our investigation into the safety of intravenous immunoglobulin produced in Scotland.
Patients and methods
We studied 16 by an independent hospital laboratory.
Results
Results were within the normal range of 8-55 IU/l. Two patients, however, had raised alanine transAccepted for publication 21 May 1985 aminase activity before treatment, presumably due to viral infection (both had clinically suspected infectious mononucleosis). Samples taken three weeks later, after treatment, gave normal results. A single sample drawn four weeks after treatment from a patient with autoimmune haemolytic anaemia (with a haemoglobin concentration of 50 g/l) gave an alanine transaminase activity of 60 IU/l. The patient was being treated at the time with cyclophosphamide, and the abnormality could have been induced by the drug.
All the specimens were negative for hepatitis B surface antigen by radioimmunoassay. One patient s specimen before treatment showed immunity to hepatitis B. Antibody to hepatitis B surface antigen (anti-HBs) attributable to the infusion was detected in all but one of the cases in samples collected one week after the start of treatment. The antibody remained detectable for three to seven weeks. Antibody levels were too low for accurate measurement or for measurement of half life.
Counterimmunoelectropheresis was used to detect a non-specific acute phase IgM antibody.4 This test is known to give positive results in cases of acute viral hepatitis types A, B, and non-A, non-B as well as some Epstein-Barr and cytomegalovirus infections, whereas in hepatitis induced by drugs the test is negative. Out of 112 samples screened for "acute phase antibody" using counterimmunoelectropheresis, 10 samples from two patients were positive on initial screening. After absorption with polymerised human immunoglobulin samples failed to react on retesting by counterimmunoelectropheresis, suggesting that the initial reactions were due to the presence of rheumatoid factor or, less likely, Gm antibodies.
Discussion
No blood product should ever be prescribed without 1192 group.bmj.com on May 6, 2017 - The data that we have presented suggest that Scottish intravenous immunoglobulin may safely be used for patients who may benefit. Although no absolute guarantee of safety can be given, the hazards of treatment with steroids, splenectomy, and immunosuppression are well known.
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